$CHI

Daily NZX update, Wednesday, July 15, 2026

A daily NZX market update said the NZX 50 was set to fall 0.1% on the day, extending a 5-day decline, while remaining up 2.1% over a month and 7.5% over a year. SkyCity (SKC) led gainers (+3%), Vista (VGL) led decliners (-3%). Channel Infrastructure (CHI) reported Q2 fuel throughput of 802m liters (-2% YoY).

Original reporting
Published Jul 15, 2026, 5:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 5:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Daily NZX update, Wednesday, July 15, 2026 — source image
Decision brief

The 30-second read

$CHINeutralLow
01

Why it matters

The only potentially tradable fundamentals in the text are the fresh operating/traffic prints for Channel Infrastructure (throughput) and Auckland International Airport (passenger movements), plus VHP’s confirmed results timing. The rest of the named stocks are primarily cited for their day’s price performance without new catalysts.

02

Market read

Traders can use CHI and AIA’s fresh monthly/quarterly operating datapoints for near-term estimate revisions, while VHP’s date can inform event-risk positioning.

03

What to watch

For AIA, the piece highlights Middle East route disruption but also notes Queenstown international traffic rose 19%, suggesting geographic mix could partially offset consolidated weakness.

Relevance 4/10Novelty 4/10Timing: as at 3:00 pm, plus upcoming catalysts for VHP results on 13 August

Background

This is a daily NZX market wrap summarizing index direction, top gainers/decliners, Smartshares ETF performance, and a few company announcements.

Company-level read

Ticker impact

$CHINeutralMedium confidence
Context

Channel Infrastructure reports Q2 fuel throughput of 802 million liters, down 2% YoY, citing elevated fuel prices and pipeline upgrade impacts.

Expected impact

Likely modest negative to neutral reaction, offset by the note that YTD volumes are in line with expectations.

Evidence & confidence

The article includes fresh, attributable operating results and project milestones, which can affect near-term estimates and sentiment.

Market effects

Airport and infrastructure operators show quantified demand and throughput pressure tied to route disruptions and operational upgrades.

New Zealand travel demand appears weaker in June, with Middle East disruptions a key drag.

Middle East disruption and elevated fuel prices are cited as drivers, linking local prints to global geopolitical and energy conditions.

Counterpoint

The article notes CHI YTD volumes are in line with expectations, implying the Q2 dip may be temporary rather than a structural deterioration.

Key entities

  • Channel Infrastructure

    Reports Q2 fuel throughput of 802 million liters, down 2% YoY, citing elevated fuel prices and pipeline upgrade impacts.

  • Auckland International Airport

    Reports June international passenger movements of 722,000, down 4% YoY, with Middle East routes down 62%.

  • Vital Healthcare Property

    Advises FY results will be released before market opens on Thursday, 13 August.

Related articles

$GMABMedAI 9/10

Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab A/S (Nasdaq: GMAB) announced Phase 2 trial results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer. The treatment showed a 45.9% objective response rate and a median duration of response of 12.1 months. The study included 109 patients and was presented at the IGCS Congress 2026. Rina-S is being evaluated in multiple Phase 3 trials for various gynecologic cancers.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Launch Backlog Tops 100 After Synspective Deal

Rocket Lab's (RKLB) launch backlog exceeded 100 missions after a 20-launch deal with Synspective. The company's backlog grew from 70+ to over 100 missions in five months. Synspective is now Rocket Lab's largest customer with 47 launches. Rocket Lab's financial backlog was $2.2bn in Q1 2026, up 20.2% from the prior quarter. The company's revenue has doubled over two years, but it remains unprofitable.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.